Covalon Technologies Ltd Can’t Be More Safe. Trades Significantly Higher


 Covalon Technologies Ltd Can't Be More Safe. Trades Significantly Higher

The stock of Covalon Technologies Ltd (CVE:COV) is a huge mover today! About 26,900 shares traded hands or 247.99% up from the average. Covalon Technologies Ltd (CVE:COV) has risen 6.00% since September 18, 2016 and is uptrending. It has outperformed by 0.52% the S&P500.
The move comes after 9 months positive chart setup for the $32.32 million company. It was reported on Oct, 18 by We have $3.11 PT which if reached, will make CVE:COV worth $22.30 million more.

More notable recent Covalon Technologies Ltd (CVE:COV) news were published by: which released: “The Goldfarb Corporation Acquires Additional Shares of Covalon Technologies Ltd.” on August 29, 2016, also with their article: “Covalon to Showcase ColActive┬« Brand of Advanced Bio-Matrix Dressings at the …” published on October 07, 2016, published: “Covalon to Exhibit at the World Union of Wound Healing Societies in Florence …” on September 26, 2016. More interesting news about Covalon Technologies Ltd (CVE:COV) were released by: and their article: “Covalon to Showcase IV Clear to Pediatric Specialists at the Association for …” published on September 16, 2016 as well as‘s news article titled: “Biomaterials Market is Expected to Reach $139 Billion by 2022, Globally …” with publication date: October 04, 2016.

Covalon Technologies Ltd. is a researcher, developer, maker and marketer of medical products intended for wound care, infection management and surgical procedures. The company has a market cap of $32.32 million. The Company’s wound care dressing products include ColActive Plus, ColActive Transfer, CovaWound Silicone, CovaWound Silicone Sacrum, CovaWound Foam, CovaWound Alginate, CovaWound Super Absorbent and CovaWound Hydrocolloid. It currently has negative earnings. The Company’s surgical and peri-operative products include SurgiClear, MediClear Post-Op Absorb and MediClear Scar.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply